ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis will pay $3.9 billion to acquire Advanced Accelerator Applications (AAA), a French radiopharmaceutical firm that makes cancer therapies and diagnostics. AAA’s sales in the first half of 2017 were only $78 million, but analysts suggest that Novartis may replace its patent-expired cancer therapy Sandostatin—which brings in $1.6 billion per year—with AAA’s Lutathera. That therapy was recently approved in Europe to treat gastroenteropancreatic neuroendocrine tumors, the cancer that killed Apple founder Steve Jobs in 2011.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter